VF
RNAZ icon

Virtu Financial’s TransCode Therapeutics RNAZ Stock Holding History

Virtu Financial’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20
Closed -$18K – 1809
2024
Q2 		$18K Sell
20
-40
-67% -$35.6K ﹤0.01% 1048
2024
Q1 		$37K Buy
+60
New +$83.8K ﹤0.01% 1070
2023
Q4 		– Sell
-1
Closed -$16K – 1938
2023
Q3 		$16K Buy
+1
New +$62.8K ﹤0.01% 1046
2023
Q1 		– Hold
0
– -$11K – 2016
2022
Q4 		– Hold
0
– – – 1370
2021
Q4 		– Hold
0
– -$54K – 2108
2021
Q3 		– Hold
0
– – – 1262

Other funds holding RNAZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
SSWM
Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Virtu Financial's RNAZ Position: Q3 2024 in Review

Virtu Financial sold out of TransCode Therapeutics (RNAZ) in Q3 2024, closing a stake of 20 shares — an estimated $18K sold.

Virtu Financial first reported a position in RNAZ in Q3 2023 and held it in 3 quarters. The position peaked at $37K in Q1 2024. 7 funds tracked by Wall St. Rank hold RNAZ as of Q3 2024.

  • Virtu Financial reported no remaining TransCode Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Virtu Financial sold 20 TransCode Therapeutics shares in Q3 2024, an estimated $18K.
  • Virtu Financial first reported a position in TransCode Therapeutics in Q3 2023 and held it in 3 quarters.
  • Virtu Financial's TransCode Therapeutics position peaked at $37K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2024.

Based on Virtu Financial's 13F filing for Q3 2024, filed 20 Nov 2024.